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Abstract 47 
 Nitric oxide (NO), a modulator of several physiological processes, is involved in different 48 
human sperm functions. We have investigated whether NO may stimulate the motility of human 49 
spermatozoa via activation of the soluble guanylate cyclase (sGC)/cGMP pathway. Sperm 50 
samples obtained by masturbation from seventy normozoospermic patients were processed by the 51 
swim-up technique. The kinetic parameters of the motile sperm-rich fractions were assessed by 52 
computer-assisted sperm analysis. After a 30-90 min incubation, the NO donor S-53 
nitrosoglutathione (GSNO) exerted a significant enhancing effect on progressive motility (77, 78 54 
and 78% vs 66, 65 and 62% of the control at the corresponding time), straight linear velocity (44, 55 
49 and 48 μm/s vs 34, 35 and 35.5 μm/s), curvilinear velocity (81, 83 and 84 μm/s vs 68 μm/s) 56 
and average path velocity (52, 57 and 54 μm/s vs 40, 42 and 42 μm/s) at 5 µM but not at lower 57 
concentrations, and in parallel increased the synthesis of cGMP. A similar effect was obtained 58 
with the NO donor spermine NONOate after 30 and 60 min. The GSNO-induced effects on 59 
sperm motility were abolished by ODQ (a specific sGC inhibitor) and mimicked by 8-Br-cGMP 60 
(a cell-permeating cGMP analog): the treatment with Rp-8-Br-cGMPS (an inhibitor of cGMP-61 
dependent protein kinases) prevented both the GSNO- and the 8-Br-cGMP-induced responses. 62 
On the opposite, we did not observe any effect of the cGMP/PKG pathway modulators on the 63 
onset of hyperactivated sperm motility. Our results suggest that NO stimulates human sperm 64 
motility via the activation of sGC, the subsequent synthesis of cGMP and the activation of 65 
cGMP-dependent protein kinases. 66 
 67 
 68 
Introduction 69 
 4
 Nitric oxide (NO) is a free radical gas which participates as a mediator in several 70 
physiopathological events, such as regulation of vascular tone, neurotransmission, apoptosis, and 71 
inflammation (Wink & Mitchell 1998). NO is synthesized by nitric oxide synthases (NOS), a 72 
family of enzymes catalyzing the conversion of L-arginine to L-citrulline and NO with a 1:1 73 
stoichiometry (Nathan & Xie 1994). Three NOS isoforms have been described: endothelial 74 
(eNOS, NOS III), neuronal (nNOS, NOS I) and inducible (iNOS or NOS II) (Nathan & Xie 75 
1994). NO has been demonstrated to play a role in a variety of functions in the human 76 
reproductive tract, including sperm motility (Lewis et al. 1996), chemotaxis (Miraglia et al. 77 
2007), and sperm-zona pellucida binding ability (Sengoku et al. 1998). NOS isoforms have been 78 
localized in the acrosome and tail of human, mouse and bovine spermatozoa (Herrero et al. 1996; 79 
Meiser & Schulz 2003), and low motility spermatozoa have been shown to exhibit aberrant 80 
patterns of eNOS immunostaining (O’Bryan et al. 1998). It has been reported that low 81 
concentrations of NO (25-100 nM sodium nitroprusside) enhance the motility of human 82 
spermatozoa (Hellstrom et al. 1994; Zhang & Zheng 1996). Accordingly, human sperm motility 83 
is inhibited by the NOS inhibitor NG-nitro-L-arginine methyl ester and by the NO scavenger 84 
methylene blue (Lewis et al. 1996; Donnelly et al. 1997). On the other hand, high NO 85 
concentrations (25-125 µM pure nitric oxide, 0.25-2.5 mM sodium nitroprusside, 12-600 μM S-86 
nitroso-N-acetylpenicillamine, 100-125 µM 3-morpholinosydnonimine) seem to exert opposite 87 
effects on the motility of human spermatozoa in vitro (Rosselli et al. 1995; Nobunaga et al. 1996; 88 
Weinberg et al. 1995). Studies on sperm capacitation showed that NO (1-100 µM spermine 89 
NONOate or diethylamine-NONOate) increases cAMP levels, thus triggering protein kinase A 90 
activation and tyrosine phosphorylation (Herrero et al. 2000) and is also involved in activation of 91 
protein extracellular signal regulated kinases (ERKs) (Thundathil et al. 2003; O’Flaherty et al. 92 
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2006). On the other hand, like in many other cell types, NO activates the soluble guanylate 93 
cyclase (sGC) in human spermatozoa (Revelli et al. 2002). The NO donors sodium nitroprusside 94 
and spermine-NONOate have been shown to increase the intracellular levels of cGMP in human 95 
(Zhang & Zheng 1996; Revelli et al. 2001) and murine (Herrero et al. 1998) spermatozoa, 96 
respectively, and recently the sGC has been identified in human sperm by immunoblotting 97 
(Willipinski-Stapelfeldt et al. 2004). Although its levels in human sperm are about 100-fold 98 
lower than the cAMP content (Willipinski-Stapelfeldt et al. 2004), cGMP has been implicated in 99 
several sperm signaling pathways functions, such as capacitation, acrosome reaction, chemotaxis 100 
and sperm-egg interaction (Revelli et al. 2001; Revelli et al. 2002, Herrero et al. 2003; Miraglia 101 
et al. 2007). cGMP is thought to modulate also sperm motility. Indeed, the cGMP-dependent 102 
phosphodiesterase (PDE) inhibitor sildenafil was reported by some authors (Lefievre et al. 2000; 103 
Cuadra et al. 2000), but not by others (Andrade et al. 2000; Aversa et al. 2000; Burger et al. 104 
2000), to increase the velocity and amplitude of lateral head displacement in human spermatozoa. 105 
Lefievre et al. observed an inhibition of sperm PDE activity with sildenafil at high 106 
concentrations, able to inhibit many PDE and causing also an increase of cAMP (Lefievre et al. 107 
2000), whereas Cuadra et al. reported that sildenafil stimulates sperm motility at much lower 108 
concentrations, quite close to the IC50 of sildenafil for the cGMP-dependent PDE (Cuadra et al. 109 
2000). A recent review of ex vivo studies suggests that sildenafil and tadalafil exert a dose-110 
dependent effect on sperm motility which is enhanced at low doses but may be reduced at high 111 
concentrations, but further investigations are required to evaluate the mechanisms by which these 112 
phosphodiesterase selective inhibitors modulate sperm motility (Dimitriadis et al. 2008).113 
 Until now no clear data show a direct relationship between exposure to NO, increase of sperm 114 
cGMP levels and changes of human sperm motility. Therefore, aim of this study has been to 115 
investigate whether human sperm motility, which is considered one of the most significant 116 
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fertility-related sperm features (Hirano et al. 2001), may be affected by NO via activation of the 117 
sGC/cGMP signaling pathway. 118 
 119 
RESULTS 120 
 Since the swim-up procedure was performed in SWM containing bicarbonate and albumin, as 121 
previously described (Miraglia et al. 2010), for a time sufficient to induce capacitation in most 122 
sperm cells, the experiments shown in each point of this paper can be considered as performed on 123 
capacitated spermatozoa (see also Materials and Methods section). Preliminary experiments of 124 
dose-dependence were performed to establish the concentration of the NO donor GSNO able to 125 
affect human sperm motility patterns. A progressively motile sperm swims forward in an 126 
essentially straight line: rapid progressive motility (A) indicates sperm swimming with a 127 
progression velocity > 25 µm/s, while slow progressive motility (B) indicates sperm swimming 128 
with a progression velocity = 5-25 µm/s (Krause & Viethen 1999). At the concentration of 5 μM, 129 
GSNO exerted a significant enhancing effect on progressive motility (A + B motility classes) at 130 
each time period considered, while at 0.1-1 μM it was not effective (Fig. 1A). When the 131 
spermatozoa were incubated with 10 µM GSNO, progressive motility (A + B classes) was 132 
comparable to those of untreated sperm (Fig 1A). To check how long the effect of 5 µM GSNO 133 
takes to develop, time-dependence experiments were performed. The increase of sperm motility 134 
induced by GSNO was not significant at 10 and 20 minutes, but only after an at least 30 minutes 135 
incubation (Fig 1B). Analyzing each class of motility we observed that the increase of 136 
progressive motility (WHO classes A + B) after treatment with GSNO was mainly due to a 137 
significant rise in the percentage of A class spermatozoa, which was counterbalanced by a 138 
parallel decrease of both C and D class spermatozoa; the amount of spermatozoa exhibiting a B 139 
pattern of motility did not change under all the experimental conditions (data not shown). On the 140 
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contrary, the motion parameters linearity (LIN) and straightness (STR) were unaffected, and no 141 
induction of HA was observed (data not shown). 142 
In the same way, GSNO strongly increased the individual parameters of sperm movement 143 
straight linear velocity (VSL), curvilinear velocity (VCL) and average path velocity (VAP) when 144 
added at 5 μM but not at 0.1-1 μM (data not shown). After the incubation with 10 µM GSNO, 145 
VSL, VCL and VAP were comparable to those of untreated sperm, thus suggesting that GSNO at 146 
this concentration was not yet toxic, but it neither could improve the sperm motility (data not 147 
shown). Spermine NONOate (SPNO) is a faster NO donor than GSNO: when incubated with 148 
several samples (n = 6) of spermatozoa, SPNO 0.5 µM significantly increased the progressive 149 
motility (A + B classes) after 30 (71.2 + 2 % vs. 51 + 1 % in controls) and 60 min (69 + 3 % vs. 150 
50 + 2 % in controls). In the same experimental conditions 0.5 µM SPNO increased significantly 151 
also VSL, VCL and VAP (data not shown). 152 
 Oxidized glutathione (GSSG), the product of GSNO decomposition, is a powerful chelator of 153 
copper ions (Singh et al. 1999). Since copper ions can influence the release of NO from GSNO, 154 
we performed further experiments to check whether the increased sperm motility that we 155 
observed after incubation with GSNO is due to the chelation of copper by GSSG. We measured 156 
sperm motility in the presence of 5 µM reduced glutathione (GSH) or GSSG, to exclude that 157 
glutathione per se, in any form, could alter the progressive motility: both GSH and GSSG had no 158 
significant effect on sperm motility (n = 4; data not shown). To chelate copper we performed also 159 
other experiments with 1 mM EDTA, and even in this case we did not observe any significant 160 
modification vs. controls and vs. GSNO alone (n = 4; data not shown). After EDTA treatment the 161 
level of calcium was about 1 mM. 162 
 Thereafter, the 5 μM concentration of GSNO was chosen to perform the subsequent 163 
experiments. The NO donor induced a significant increase of sperm progressive motility 164 
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measured by CASA after incubation with freshly ejaculated human samples for 30, 60 and 90 165 
min (Fig. 2). The sGC inhibitor ODQ did not affect the progressive motility when added alone, 166 
but completely blunted its GSNO-elicited increase at each time period (Fig. 2). On the other 167 
hand, 8-Br-cGMP, a cell-permeating cGMP analog, exerted a significant enhancing effect on 168 
progressive motility per se and completely reversed the inhibitory effect of ODQ on the GSNO-169 
stimulated increase (Fig. 2). Finally, the PKG inhibitor Rp-8-Br-cGMPS, which per se did not 170 
modify the sperm progressive motility, abolished the effects of GSNO and 8-Br-cGMP on this 171 
motion parameter (Fig. 2).  172 
 In order to confirm the role of NO in this process, we measured also the progressive motility 173 
in the presence of the NO scavenger PTIO. 100 µM PTIO did not affect sperm motility when 174 
used alone, but when co-incubated with GSNO (5 µM) it completely reversed the increase of 175 
motility induced by GSNO (Fig. 3). In the presence of 20 μl of packed fresh red blood cells, used 176 
as reservoirs of the NO scavenger oxyhemoglobin, the motility results were the same observed 177 
with PTIO (n = 3; data not shown). To this purpose, we incubated the spermatozoa at the reported 178 
concentrations used in the other experiments and for the indicated times (30, 60, 90 min) in the 179 
lower compartment of a transwell system (having a polycarbonate transwell insert membrane 180 
with pore sizes of 3 μm, in 24 well plates provided by Corning Incorporated, Apton, MA), 181 
containing in the upper compartment 20 μl of packed fresh red blood cells in 0.5 ml of SWM. 182 
After each incubation time the upper compartment was taken out and the sperm motility 183 
parameters were measured as described in the Materials and Methods section. 184 
 We also evaluated the effect of NO on sperm kinetic parameters assessed by CASA. In the 185 
presence of GSNO, the straight linear velocity (VSL) markedly increased, an effect that was 186 
abolished by ODQ (which per se did not modify this motion parameter), as shown in Fig. 4A; the 187 
cGMP analog 8-Br-cGMP significantly stimulated VSL, and bypassed the inhibition exerted by 188 
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ODQ on the GSNO-evoked VSL increase (Fig. 4A). The co-incubation with Rp-8-Br-cGMPS 189 
completely blunted the positive action of both GSNO and 8-Br-cGMP on VSL (Fig. 4A). 190 
 The same pattern of response was observed when considering the curvilinear velocity (VCL) 191 
(Fig. 4B) and the average path velocity (VAP) (Fig. 4C) of human spermatozoa treated under the 192 
same experimental conditions.  193 
 Finally, under the same experimental conditions GSNO significantly increased the synthesis of 194 
cGMP in human spermatozoa at each incubation time considered: the absence of a significant 195 
time-dependence suggests that GSNO exerts a maximal effect already after 30 min, and that 196 
between 30 and 90 min the synthesis of cGMP is maintained in a steady state condition. The 197 
effect of GSNO was completely abolished by ODQ; as expected, after incubation with 8-Br-198 
cGMP, both alone and together with GSNO and ODQ, the cGMP intracellular level was 199 
significantly higher than the control level (Fig. 5). Also in this case, no time-dependence was 200 
observed, suggesting that in our experimental conditions the entry of 8-Br-cGMP into the cells 201 
and its degradation were balanced throughout the time of investigation. 202 
 Since the measurement of intracellular cGMP was performed in the presence of the 203 
phosphodiesterase inhibitor IBMX to inhibit cGMP hydrolysis, we performed further motility 204 
experiments on samples pre-treated for 20 min with 200 µM IBMX and then for 30, 60 and 90 205 
min with 5 µM GSNO: we observed that the pre-treatment with IBMX did not influence the 206 
enhancement of sperm motility induced by NO (Fig. 3). 207 
 208 
DISCUSSION 209 
 The nitric oxide/cGMP signaling pathway modulates several physiopathological events of the 210 
mammalian reproductive tract (Rosselli et al. 1998). As far as sperm functions are concerned, NO 211 
released by sodium nitroprusside has been shown to play an important role in mouse sperm 212 
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hyperactivation (Herrero et al. 1994) and in the maintenance of post-thaw human sperm motility 213 
and viability (Hellstrom et al. 1994). Moreover, spermatozoa themselves synthesize NO, and the 214 
basal release of this free radical by spermatozoa has been observed to be higher in 215 
normozoospermic than in asthenospermic sperm samples; accordingly, normal spermatozoa 216 
express more eNOS and generate more nitrite than spermatozoa of asthenospermic samples 217 
(Lewis et al. 1996). Furthermore, the NO scavenger methylene blue and the NOS inhibitor NG-218 
nitro-L-arginine methyl ester have been shown to inhibit human sperm motility (Lewis et al. 219 
1996; Donnelly et al. 1997). On the other hand, when female mice null for one of the three NOS 220 
isoforms (eNOS, nNOS and iNOS, respectively) mated with null male mice the rate of in vitro 221 
fertilization was not inhibited (Yang et al. 2005): this observation does not change the meaning 222 
of our results, because in the absence of a NOS isoform NO can be produced by another isoform. 223 
Furthermore, these results were obtained in mice. Finally, in spermatozoa NO can be generated as 224 
a consequence of a direct hydrogen peroxide attack on arginine (Aitken et al. 2004). 225 
 In the present work we provide further evidence suggesting a role of the cGMP signaling 226 
pathway in human sperm motility. The NO donor GSNO significantly increased the sperm 227 
forward progressive motility after 30-90 min of incubation: GSNO significantly augmented the 228 
percentage of A class sperm without modifying the overall amount of B class sperm; it also 229 
decreased the percentage of in situ motile (C class) and immotile (D class) cells. In parallel, the 230 
NO donor stimulated the sperm kinetic parameters assessed by CASA, straight linear velocity 231 
(VSL), curvilinear velocity (VCL) and average path velocity (VAP). This is in accordance with a 232 
previous study reporting that sodium nitroprusside increased human sperm motility (Zhang & 233 
Zheng 1996): such effect was detectable at 25-100 nM but not at 200-400 nM, whereas we 234 
observed a significant motility enhancement using 5 μM GSNO. This difference may be due to 235 
the different NO donor employed and the different experimental procedure used to measure 236 
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sperm motility: indeed, that study evaluated a trans-membrane migration ratio (the proportion of 237 
human spermatozoa moving across a membrane separating two chambers) (Zhang & Zheng 238 
1996), whereas CASA calculates the percentage of cells exhibiting a forward progressive motility 239 
and the kinetic parameters of each cell. 240 
 Compared to GSNO (having an half-life of hours, ranging from 10 to 38 h) (Nikitovic & 241 
Holmgren 1996; Mancuso et al. 2003), SPNO is a faster NO donor, with a half-life of 39 minutes 242 
at 37°C and pH 7.4 (Keefer et al. 1996). In further experiments using SPNO as NO donor, we 243 
observed that also the incubation with SPNO 0.5 µM significantly increased the progressive 244 
motility (A + B classes), VSL, VCL and VAP after 30 and 60 min. 245 
 In a previous work we demonstrated that GSNO and 8-Br-cGMP exerted a significant 246 
chemotactic effect on human spermatozoa without affecting their motion parameters (Miraglia et 247 
al. 2007). In that study both substances were used at different concentrations and time periods 248 
compared to those employed in this investigation: GSNO exerted a chemoattractant effect at 100 249 
nM, while in this study it was ineffective on motility even at 1 µM. On the other hand, 8-Br-250 
cGMP was used in the previous study at a 1 mM concentration, two-fold higher than the one used 251 
in the present work. Moreover, in our previous work we investigated the sperm motion 252 
parameters only after 20 min of incubation with GSNO and 8-Br-cGMP, whereas in the present 253 
research we employed longer (30-90 min) time periods of observation (Miraglia et al. 2007). 254 
Since the intracellular levels of cGMP measured after incubation with either GSNO or 8-Br-255 
cGMP were respectively similar in both experimental works, in spite of the different incubation 256 
times and concentrations used, it is likely that these compounds exert a significant effect on 257 
sperm motility only when the level of intracellular cGMP is maintained increased for a time 258 
longer than the one necessary for cGMP to modulate chemotaxis. This suggestion may make 259 
sense, since it is reasonable to suppose that at a first time sperm needs to be simply oriented 260 
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versus a source of NO and only subsequently, when the increase of cGMP shows to be 261 
persistently high, the motility should increase. 262 
 The effect of GSNO on sperm motility is indeed mediated by an increased synthesis of cGMP, 263 
as the sGC inhibitor ODQ blunted the GSNO-elicited motility and abolished the increase of 264 
intracellular cGMP induced by GSNO. The treatment with the cell-permeating cGMP analog 8-265 
Br-cGMP, which augmented by nearly 4-fold the intracellular content of cyclic nucleotide, 266 
strongly increased the forward progressive motility and the kinetic parameters VSL, VCL and 267 
VAP. Moreover, 8-Br-cGMP reversed the inhibitory effect of ODQ on the GSNO-evoked 268 
increase of progressive motility and velocity, confirming that ODQ inhibited sperm motility by 269 
lowering the intracellular level of cGMP. 270 
 Taken together, these findings suggest that NO stimulates human sperm motility via the 271 
activation of sGC and the subsequent synthesis of cGMP. One of the main targets of cGMP in 272 
many tissues is a family of serine/threonine kinases, the PKGs (Hofmann 2005). Rp-8-Br-273 
cGMPS, a PKG inhibitor (Kawada et al. 1997), abolished the positive effect exerted by both 274 
GSNO and 8-Br-cGMP on sperm motility, suggesting that the effect of endogenous or exogenous 275 
cGMP on sperm movement is mediated by PKG activity. Thus, from our data PKG seems to play 276 
a role in mediating not only the NO-elicited chemotaxis and the acrosome reaction (Miraglia et 277 
al. 2007; Revelli et al. 2001), but also in modulating several sperm motion patterns. On the other 278 
hand, we did not observe any effect of the cGMP/PKG pathway modulators on the onset of 279 
hyperactivated sperm motility. 280 
 It is widely acknowledged that spermatozoa in the human female reproductive tract have close 281 
and prolonged contact with a significant array of NO-producing cells (Rosselli et al. 1998; Sun et 282 
al. 2005; Machado-Oliveira et al. 2008): the exact sites of NO production in the female genital 283 
tract remain to be investigated, but Machado-Oliveira and colleagues (Machado-Oliveira et al. 284 
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2008) showed that detectable amounts of NO are produced in human cumulus fragments and 285 
oviduct explants. This free radical is relatively unreactive, and is able to diffuse from the cell in 286 
which it is generated to the neighbor cells, covering long distances in a very short time (Kröncke 287 
et al. 1997). Moreover, spermatozoa themselves produce and release NO during their trip along 288 
the upper female genital tract. This suggests that a complex interaction between spermatozoa, 289 
granulosa cells and other cells of the female reproductive tract may submit human sperm to 290 
amounts of NO that are sufficient to elicit in vivo the changes of motility we have observed in 291 
vitro. 292 
 It is generally accepted that a good sperm motility is a major component of normal male 293 
fertility. Men with poorly motile or immotile sperm are typically infertile or sterile (Turner 294 
2006). A deeper knowledge of the role of the NO/cGMP/PKG signaling pathway in the 295 
physiopathology of sperm motility could help to pharmacologically improve the fertilization 296 
capacity of human sperm or, alternatively, could lead to the development of an effective and safe 297 
male contraceptive based on sperm motility impairment. 298 
 299 
Materials and methods 300 
Reagents 301 
 Sperm Washing Medium (SWM) was supplied by Celbio (Milan, Italy): it is based on the 302 
Modified Human Tubal Fluid (Quinn et al. 1985), containing sodium bicarbonate (4 mM), Hepes 303 
buffer (21 mM), human serum albumin (5 mg/ml). S-nitrosoglutathione (GSNO), 1H-304 
[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ), 8-bromo-cGMP (8-Br-cGMP), and 3-305 
isobutyl-1-methylxanthine (IBMX) were purchased from Sigma Chemical Co. (St. Louis, MO). 306 
The inhibitor of cGMP-dependent protein kinases (PKGs) 8-bromoguanosine-3’,5’-307 
monophosphorothioate Rp-isomer (Rp-8-Br-cGMPS) was from Biolog Life Science Institute 308 
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(Bremen, Germany). The [3H]cGMP RIA kit was obtained from Amersham International 309 
(Buckinghamshire, UK). 310 
Collection and preparation of sperm samples 311 
 Sperm samples were obtained by masturbation after 3-5 days of sexual abstinence from 312 
seventy normozoospermic patients belonging to couples presenting for infertility evaluation. 313 
Each donor gave informed consent allowing the use of his semen for our experiments. The 314 
Institutional Review Board approval was obtained from the internal ethical committee that 315 
authorized the use of semen samples submitted to semen examination for experimental purposes. 316 
All samples were allowed to liquefy for at least 30 minutes at 37°C, then they were evaluated for 317 
sperm concentration, motility and morphology according to World Health Organization 318 
guidelines (World Health Organization 2001). Only specimens with normal parameters 319 
(concentration > 20 x 106 spermatozoa/ml, progressive motility > 50%) were used in the 320 
experiments. 321 
 Motile spermatozoa were capacitated by the swim-up technique (37°C for 75 min in a 5% CO2 322 
atmosphere) using SWM, as previously described (Miraglia et al. 2010). The presence of round 323 
cells was initially below 1x106 in all sperm samples, and was minimal if not absent after the 324 
swim-up technique in the final suspension. After swim-up, the motile sperm-rich fraction was 325 
centrifuged at 600 g for 10 min, the supernatant was discarded and the pellet re-suspended in 326 
SWM. The concentration of the spermatozoa suspensions was assessed in a Makler counting 327 
chamber (Sefi Medical Instruments, Haifa, Israel) under a phase-contrast microscope 328 
(magnification 20 X), and adjusted to approximately 100 x 106 cells/ml. The dose-dependent 329 
effect of GSNO on sperm motility was investigated in the first 25 samples (20×106 cells/200 µl), 330 
the effect of the modulation of the cGMP pathway on sperm kinetic parameters was studied in the 331 
subsequent 40 samples (20×106 cells/200 µl), and finally the ability of the cGMP-modulating 332 
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agents to modify the intracellular cGMP content was checked in the last 5 samples (15×106 333 
cells/500 µl). GSNO was not toxic at the concentrations used, as checked by the eosin Y 334 
exclusion test (Cincik et al. 2007). 335 
Analysis of Motility Parameters 336 
 Aliquots of sperm suspension (200 µl) in SWM, each containing 20×106 cells, were incubated 337 
under the experimental conditions indicated in Results. Sperm motility parameters were assessed 338 
by computer-assisted sperm analysis (CASA) (CGA-WLJY-9000, CGA Distribution, Florence, 339 
Italy) after 30, 60 and 90 min of incubation. The following kinetic parameters were measured: 340 
percentage of spermatozoa exhibiting a forward progressive motility (A+B WHO classes), in situ 341 
motility (C WHO class), or no motility (D WHO class); straight linear velocity (VSL, which 342 
represents the average velocity, expressed in µm/s, measured from the beginning to the end of a 343 
linear track); curvilinear velocity (VCL, which is the average velocity measured over the actual 344 
point-to-point track followed by the cell, expressed as μm/s); average path velocity (VAP, 345 
corresponding to the average velocity of smoothed cell’s pathway, expressed in µm/s); linearity 346 
[LIN = (VSL/VCL) x 100]; straightness (STR, the percentage of correspondence of the cell’s 347 
pathway to a straight line, with 100% corresponding to the maximal extent of straightness) 348 
(Mortimer 1997). Sperm hyperactivation (HA) was also considered, using the following 349 
parameters: VCL > 70 µm/s, ALH > 7 µm, LIN < 30%, VSL < 30 µm/s (Green & Fishel 1999). 350 
Measurement of intracellular cGMP 351 
 The level of intracellular cGMP was measured as previously described (Miraglia et al. 2007) 352 
Briefly, aliquots of sperm suspensions (500 μl), each containing 15 x 106 cells, were pre-treated 353 
for 20 min with the phosphodiesterase inhibitor IBMX (200 μM) to inhibit cGMP hydrolysis, and 354 
then were co-incubated for 30, 60 or 90 min with the same substances (GSNO, ODQ, 8-Br-355 
cGMP) used for the assessment of motility parameters, alone or differently combined. 356 
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Subsequently, the samples were centrifuged at 13,000 g for 1 min, the supernatants were 357 
discarded and 50 µl of absolute ethanol were added to the pellets; ethanol was then evaporated by 358 
vacuum centrifugation, and 350 μl of Tris/EDTA buffer (50 mM Tris-HCl, 4 mM EDTA, pH 7.5) 359 
were added. After 10 min, 100 μl of supernatant were tested for the cGMP level with a 360 
[3H]cGMP immunoassay system. The cGMP content was expressed as pmol/106 cells. Cross-361 
reactivity of the [3H]cGMP immunoassay system with cAMP was less than 0.001%. 362 
Statistical analysis 363 
 All data are provided as means ± SEM. The results were analyzed by a One-Way Analysis of 364 
Variance (ANOVA) and Tukey’s and Bonferroni’s test (software: SPSS 11.0 for Windows, SPSS 365 
Inc., Chicago, IL), including the different times of incubation in the global significance 366 
evaluation. A p value < 0.05 was considered significant. 367 
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Figure 1. Effect of GSNO on sperm motility patterns. 521 
A. The percentage of spermatozoa exhibiting a forward progressive motility (A + B WHO 522 
classes) was recorded by computer-assisted sperm analysis (CASA) after a 30 min (white bars), 523 
 24
60 min (black bars) or 90 min (hatched bars) incubation of 20×106 cells /200 μl with 0.1-10 μM 524 
S-nitrosoglutathione (GSNO). All data are presented as means + SEM (n = 25). Significance vs. 525 
control at the corresponding incubation time: * p < 0.05. 526 
B. The percentage of spermatozoa exhibiting a forward progressive motility (A + B WHO 527 
classes) was recorded by CASA after a 10, 20, 30, 60 or 90 min incubation of 20×106 528 
spermatozoa/200 µl with 5 µM GSNO. All data are presented as means + SEM (n = 4). 529 
Significance vs. ctrl : * p < 0.05. 530 
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Figure 2. Effect of the modulation of the cGMP pathway on human sperm progressive 535 
motility. The forward progressive motility (motility classes A + B) was assessed by CASA in 536 
human spermatozoa (20×106/200 μl) incubated for 30, 60 or 90 min with the following 537 
substances, alone or differently combined: S-nitrosoglutathione (GSNO, 5 μM), 1H-538 
[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ, 10 μM), 8-bromo-cGMP (8-Br-cGMP, 500 539 
μM), Rp-8-Br-cGMPS (Rp, 10 μM). All data are presented as means + SEM (n = 40). 540 
Significance vs. respective CTRL: * p < 0.001; vs. GSNO: ° p < 0.001; vs. GSNO+ODQ: § p < 541 
0.001; vs. 8-Br-cGMP: ^ p < 0.001. 542 
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 545 
Figure 3. Effect of GSNO, PTIO and IBMX on sperm motility patterns. The forward 546 
progressive motility (motility classes A + B) was assessed by CASA in human spermatozoa 547 
(20×106/200 μl) incubated for 30, 60 or 90 min with the following substances, alone or 548 
differently combined: 5 µM GSNO, 100 µM PTIO, 200 µM IBMX. In the case of IBMX, the 549 
spermatozoa were pre-treated for 20 min with IBMX before being incubated with 5 µM GSNO 550 
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for 30, 60 or 90 min. All data are presented as means + SEM (n =  4). Significance vs. respective 551 
ctrl: * p<0.05; vs. GSNO: ° p<0.05. 552 
 553 
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Figure 4. Effects of the modulation of the cGMP pathway on straight linear velocity (VSL, 557 
panel A), curvilinear velocity (VCL, panel B) and average path velocity (VAP, panel C) of 558 
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human spermatozoa. VSL, VCL and VAP were measured by CASA on human spermatozoa 559 
(20×106/200 μl) incubated for 30, 60 or 90 min in the absence (CTRL) or presence of the 560 
following agents, alone or differently combined: 5 μM GSNO, 10 μM ODQ, 500 μM 8-Br-561 
cGMP, 10 μM Rp-8-Br-cGMPS (Rp). Results are shown as means + SEM (n = 40). 562 
A. Significance vs. CTRL: * p < 0.001; vs. GSNO: ° p < 0.001; vs. GSNO+ODQ: § p < 0.001; vs. 563 
8-Br-cGMP: ^ p < 0.001. 564 
B.  Significance vs. CTRL: * p < 0.001; vs. GSNO: ° p < 0.005; vs. GSNO+ODQ: § p < 0.01; vs. 565 
8-Br-cGMP: ^ p < 0.005. 566 
C. Significance vs. CTRL: * p < 0.001; vs. GSNO: ° p < 0.001; vs. GSNO+ODQ: § p < 0.001; vs. 567 
8-Br-cGMP: ^ p < 0.001. 568 
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 572 
Figure 5. Intracellular cGMP levels in human spermatozoa treated with agents modulating 573 
the cGMP pathway. Sperm samples (15 x 106 cells/500 μl) were pre-treated with 200 µM IBMX 574 
for 20 min, and subsequently they were incubated for 30, 60 or 90 min in the absence (CTRL) or 575 
presence of the following substances, alone or in co-incubation: 5 μM GSNO, 10 μM ODQ, 500 576 
μM 8-Br-cGMP. Then, intracellular cGMP concentration was determined as described under the 577 
Materials and Methods section. The measurements were performed in triplicate, and data are 578 
presented as means + SEM (n = 5). Significance vs. CTRL: * p < 0.001; vs. GSNO: ° p < 0.005; 579 
vs. GSNO+ODQ: § p < 0.001. 580 
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